Company Information
Industry 卫生和社会工作业
Company Introduction 爱尔眼科医院集团股份有限公司是一家眼科医疗机构,公司主要为向患者提供各种眼科疾病的诊断、治疗及医学验光配镜等眼科医疗服务.本公司是我国规模最大的眼科医疗机构之一,本公司是国内发展速度最快的眼科医疗机构之一.公司在2008年及2009年中国最具投资价值企业评选中,从全国近千家提名企业中脱颖而出,连续两年入选"清科--中国最具投资价值企业50强".公司的[爱尔]品牌的市场影响力和渗透力迅速提升,成为具有全国影响力的眼科品牌.2006年4月,本公司被《人民日报·健康时报》评选为"全国最具实力特色眼科医院".2005年,「爱尔」被评选为湖南省著名品牌.在临床研究方面,公司近年来取得了较大的突破:《儿童白内障手术及术后视功能康复的系列研究》在湖北省科技厅主持的科研成果鉴定会上获"国内领先,具有国际水平"鉴定意见;《现代斜弱视治疗的规范化检查》课题中标为上海市长宁区卫生系统2007年度科研项目;本公司与中国协和医科大学合作开展的《湖南衡山白内障家系致病基因的定位与突变检测工作》课题成为国家科技部遗传资源重点项目(2004DKA30490)及国家基础研究重点项目(2001CB5103)。
Main Business 各类眼科疾病诊疗、手术服务与医学验光配镜
Legal Representative 陈邦
Top Executives
董事长:陈邦
副董事长:李力
董事:韩忠,吴士君
独立董事:陈收,高国垒,郭月梅
Top 5 Shareholder
Shareholder name Nature Holding Date
爱尔医疗投资集团有限公司流通A股34.33%31/03/2024
陈邦限售股+流通A股15.48%31/03/2024
香港中央结算有限公司流通A股3.51%31/03/2024
李力限售股+流通A股3.46%31/03/2024
中国工商银行股份有限公司-中欧医疗健康混合型证券投资基金流通A股2.17%31/03/2024
Company Secretary 吴士君
Solicitors 湖南启元律师事务所
Auditors 中审众环会计师事务所(特殊普通合伙)
Tel No 0731-82570739;0731-85136739
Fax No 0731-85174161
Website www.aierchina.com
Email zhengquanbu@yeah.net
Company Address
Register: 湖南省长沙市天心区芙蓉南路一段188号爱尔大厦
Office: 湖南省长沙市天心区芙蓉南路一段188号爱尔大厦北塔
Listing Date 30/10/2009
Shares Capital
Shares Capital: 9,328,411,413
Total A Share: 9,328,411,413
Listed A Share: 7,905,004,112
Non-tradable A Share: 1,423,407,301
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.364
DPS(RMB)* ¥ 0.150
NBV Per Share(RMB)* ¥ 2.021
Market Capitalization(RMB) 101.896B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.